Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment

OBJECTIVE: Crizotinib is recommended as the first-line therapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Despite its initial efficacy, patients ultimately acquire resistance to crizotinib within 1 year. In such patients, the optimal sequential therapy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Chin J Cancer Res
Main Authors: Xu, Haiyan, Ma, Di, Yang, Guangjian, Li, Junling, Hao, Xuezhi, Xing, Puyuan, Yang, Lu, Xu, Fei, Wang, Yan
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6513749/
https://ncbi.nlm.nih.gov/pubmed/31156305
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2019.02.09
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados